Articles by Dawn M. Boothe, DVM, PhD, DACVIM, DACVCP - Veterinary Medicine
  • SEARCH:
Medicine Center
DVM Veterinary Medicine Featuring Information from:

ADVERTISEMENT

Articles by Dawn M. Boothe, DVM, PhD, DACVIM, DACVCP

Antimicrobial resistance: are we there yet? (Proceedings)

Nov 1, 2010

The ability of organisms to develop resistance to an antimicrobial varies with the species and strain. Many organisms remain predictably susceptible to selected drugs (eg, Brucella, Chlamydia); whereas others are becoming problematic (Pasteurella multocida).

A case-based approach to therapeutic drug monitoring: increasing the likelihood of success (Proceedings)

Nov 1, 2010

The success of any fixed dosing regimen most often is based on the patient's clinical response to the drug. Fixed dosing regimens are designed to generate plasma drug concentrations (PDC) within a therapeutic range, ie, achieve the desired effect while avoiding toxicity.

Transdermal gel drug therapy: fuss or must? (Proceedings)

Nov 1, 2010

Individualized drug therapy increasingly is being recognized as an important aspect of health care for both human and veterinary medicine. However, the number of animal drugs approved by the Food and Drug Administration (FDA) is sparse in comparison to those for human patients.

Anticonvulsant therapy: the new and the old (Proceedings)

Nov 1, 2010

Successful control of seizures with anticonvulsant drugs reflects a balance in achieving seizure control while minimizing undesirable drug side effects. Variability in the disposition of anticonvulsants and interactions among them and other drugs are important confounders of successful therapy.

Designing a dosing regimen based on time vs. concentration dependency: a dynamic challenge (Proceedings)

Nov 1, 2010

Dosing regimens for antimicrobials exemplify the integration of pharmacokinetics (what the body does to the drug) and pharmacodynamics (what the drug does to the body). For antimicrobial therapy, the "body" is the microbe.

Nutraceuticals: myth or must? (Proceedings)

Nov 1, 2010

Close to 30% of pet owners have used or considered the use of novel ingredients (eg, nutraceuticals and herbs/botanicals) in their animals. In the USA, approximately 90% of veterinarians sell some type of novel ingredient and the current market of veterinary novel ingredients is between $20 and $50 million per year.

Drug labels: friend or foe? (Proceedings)

Nov 1, 2010

Today's drug package insert (DPI) can be a powerful ally in the selection and judicious use of a drug. The information that it provides might be categorized as either Product Description, Product Efficacy or Product Safety with some overlap among the categories.

The perils of compounding (Proceedings)

Apr 1, 2009

Compounding is and always has been a critical component to the provision of individualized drug care to the small animal patient.

Nonsteroidal anti-inflammatories in cats (Proceedings)

Apr 1, 2009

The cat as a species represents a therapeutic challenge when trying to use NSAIDs safely.

ADVERTISEMENT

Click here